Worth reading
38Recurring
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
46
Millions of yen (year-on-year change in operating profit)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales458Millions of yenYear on year +2.3%Progress 14.5%
Operating profit30Millions of yenProgress 15.2%
Ordinary income18Millions of yenProgress 9.1%
Net income attributable to owners of the parent12Millions of yenProgress 6.5%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥1.33
Financial position at period-end
Total assets8,355Millions of yen
of which net assets 7,777 Millions of yenEquity ratio 91.0%vs. prior year-end +0.7pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueHealthcare-Related Businesses 423 Millions of yen (YoY +2.3%), Real Estate 34 Millions of yen (YoY +1.1%)
Segment profitHealthcare-Related Businesses 116 Millions of yen (YoY +74.7%), Real Estate 14 Millions of yen (YoY +3.8%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales3,166 Millions of yen (YoY +58.0%)
Operating profit197 Millions of yen
Ordinary income198 Millions of yen
Net income186 Millions of yen
Revision to Earnings ForecastNo revision
Annual Dividend Forecast¥0 → ¥3
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies / Name of newly added company Not disclosed / Excluded 0 companies / Excluded Company Name Not disclosed
Impairment lossNo applicable matters.
Breakdown of extraordinary income (loss)No applicable matters.
Depreciation and amortization17 Millions of yen
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNone (対象者：Not disclosed)
Issued Shares at Period-End10,408,500 shares
Treasury Shares at Period-End639 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | 458 Millions of yen (YoY +2.3%) |
| Operating profit | 30 Millions of yen |
| Ordinary income | 18 Millions of yen |
| Profit attributable to owners of the parent | 12 Millions of yen |
| Net income per share | ¥1.33 |
| Equity ratio | End of the current fiscal period 91 / End of previous period 90.3 |
| Total assets | 8,355 Millions of yen |
| Net assets | 7,777 Millions of yen |
| Full-year earnings forecast | Net Sales 3,166 Millions of yen (YoY +58.0%) / Operating profit 197 Millions of yen / Ordinary income 198 Millions of yen / Net income 186 Millions of yen |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥0 → ¥3 |
| Segment revenue | Healthcare-Related Businesses 423 Millions of yen (YoY +2.3%), Real Estate 34 Millions of yen (YoY +1.1%) |
| Segment profit | Healthcare-Related Businesses 116 Millions of yen (YoY +74.7%), Real Estate 14 Millions of yen (YoY +3.8%) |
| Depreciation and amortization | 17 Millions of yen |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Name of newly added company Not disclosed / Excluded 0 companies / Excluded Company Name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 10,408,500 shares |
| Treasury Shares at Period-End | 639 shares |
Items this document does not state (12)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogDisclosure regarding the going concern assumptionMaterial subsequent eventsFactors Behind Changes in Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The medical-related business reported revenue of ¥423 million and operating profit of ¥116 million, while the real estate-related business reported revenue of ¥34 million and operating profit of ¥14 million. No specific reasons for the increases in revenue and profit are provided.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.